Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 41-50 of 121 for

Edit search filters
  1. A Study of Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer

    Rochester, MN

  2. A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression

    Rochester, MN

  3. Study of SC-003 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

    Rochester, MN

  4. A Study to Evaluate Precision Pharmacogenomics in Cancer Patients

    Scottsdale/Phoenix, AZ

  5. Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Rochester, MN

  6. A Study Evaluating Pembrolizumab and Epacadostat in Treating Participants With Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma

    Rochester, MN

  7. Carboplatin and Gemcitabine Hydrochloride With or Without VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Rochester, MN, Scottsdale/Phoenix, AZ

  8. Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

    Rochester, MN, Scottsdale/Phoenix, AZ, Jacksonville, FL

  9. Veliparib and Topotecan Hydrochloride in Treating Patients with Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

    Rochester, MN

.

Mayo Clinic Footer